{"disease":{"id":"anal-squamous-cell-carcinoma","name":"anal squamous cell carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05973487","title":"A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":840,"lead_sponsor_name":"TScan Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03233711","title":"Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":344,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05328765","title":"A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Latin American Cooperative Oncology Group","has_results":false},{"nct_id":"NCT04429542","title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":292,"lead_sponsor_name":"Bicara Therapeutics","has_results":false},{"nct_id":"NCT04166318","title":"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":252,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06651957","title":"Anal High-risk HPV, HSIL, and Microbiome Among Hispanic Peoples Living With HIV (PLWH)","phase":"","overall_status":"COMPLETED","enrollment_count":217,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT05438836","title":"Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":205,"lead_sponsor_name":"Herlev Hospital","has_results":false},{"nct_id":"NCT04444921","title":"EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":205,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05551117","title":"A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":192,"lead_sponsor_name":"MacroGenics","has_results":true},{"nct_id":"NCT04802876","title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"SOLTI Breast Cancer Research Group","has_results":false},{"nct_id":"NCT07217171","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"EvolveImmune United, Inc","has_results":false},{"nct_id":"NCT03074513","title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":133,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05544929","title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":126,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07280377","title":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":122,"lead_sponsor_name":"Oncolytics Biotech","has_results":false},{"nct_id":"NCT03061435","title":"Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.","phase":"NA","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Dr. Danielle Vicus","has_results":false},{"nct_id":"NCT04272034","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":105,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT05374252","title":"Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":102,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT06050707","title":"MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT03849469","title":"A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT04596033","title":"TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":49,"lead_sponsor_name":"Genocea Biosciences, Inc.","has_results":false},{"nct_id":"NCT05130073","title":"4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04929028","title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02314169","title":"Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04894370","title":"Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":34,"lead_sponsor_name":"Centre Hospitalier Universitaire de Besancon","has_results":false},{"nct_id":"NCT04221893","title":"Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers","phase":"NA","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT05060471","title":"PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04857528","title":"Detecting HPV DNA in Anal and Cervical Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT05838391","title":"Adaptive Radiation in Anal Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT05686226","title":"E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Christian Hinrichs","has_results":false},{"nct_id":"NCT05639972","title":"E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Christian Hinrichs","has_results":false},{"nct_id":"NCT03690921","title":"Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT04499352","title":"A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05582031","title":"Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Translational Research in Oncology","has_results":false}],"total":35},"guidelines":[],"source":"Drug Landscape verified database"}